Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)

In the ATEMPT trial, adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel plus trastuzumab (TH) for stage I HER2-positive breast cancer improved patient-reported outcomes (PROs), while maintaining excellent disease outcomes. We report treatment discontinuation and use multivariable models t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sella, Tal, Zheng, Yue, Tayob, Nabihah, Ruddy, Kathryn J., Freedman, Rachel A., Dang, Chau, Yardley, Denise, Isakoff, Steven J., Valero, Vicente, DeMeo, Michelle, Burstein, Harold J., Winer, Eric P., Wolff, Antonio C., Krop, Ian, Partridge, Ann H., Tolaney, Sara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712612/
https://www.ncbi.nlm.nih.gov/pubmed/36450763
http://dx.doi.org/10.1038/s41523-022-00495-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712612/
https://www.ncbi.nlm.nih.gov/pubmed/36450763
http://dx.doi.org/10.1038/s41523-022-00495-x

Ejemplares similares